Traws Pharma, Inc. received a notification from Nasdaq on July 29, 2026, indicating non-compliance with the Minimum Bid Price Requirement because its common stock closed below $1.00 per share for at least 30 consecutive business days. The listing remains effective as the company has until January 25, 2027, to regain compliance by maintaining a closing price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting proceedings. Traws Pharma operates in the biopharmaceutical industry, focusing on drug discovery and development.

Traws Pharma, Inc. filed a prospectus supplement dated July 10, 2026, to its effective shelf registration statement, enabling the company to offer and sell common stock with an aggregate offering price of up to $5,575,709 through its existing At The Market (ATM) offering agreement with Citizens JMP Securities, LLC. This sale is subject to ability to use its current "baby shelf

At its 2026 Annual Meeting of Stockholders held on July 8, 2026, Traws Pharma, Inc. stockholders approved an amendment to the company's 2021 Incentive Compensation Plan to increase the available common stock for issuance by 2,000,000 shares. Additionally, shareholders approved the issuance of common stock upon the exercise of Series B and Series C Warrants issued to certain investors under an April 15, 2026, Securities Purchase Agreement, in compliance with Nasdaq listing rules. The meeting also resulted in the election of seven directors and the ratification of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year. Traws Pharma, Inc. is a pharmaceutical company.